中文译文：表现为不确定葡萄糖耐量（INDET）的囊性纤维化患者的特征。
Characterization of patients with cystic fibrosis presenting an indeterminate glucose tolerance (INDET).
机构信息
Institut de Recherches Cliniques de Montréal, Montréal, Québec H2W 1R7, Canada; Department of Nutrition, Université de Montréal, Montréal, Québec H3T 1A8, Canada.
Department of Medicine, Université de Montréal, Montréal, Québec H3T1J4, Canada.
出版信息
J Cyst Fibros. 2016 Jan;15(1):127-32. doi: 10.1016/j.jcf.2015.03.001. Epub 2015 Mar 27.
BACKGROUND
CFRD is preceded and associated with a significantly increased morbidity and mortality. We aimed to characterize a large newly established glucose tolerance subgroup named INDET (indeterminate; 1-h oral glucose tolerance test (OGTT)>11.0 but 2h-OGTT<7.8 mmol/L) in adult patients with cystic fibrosis (CF).
METHODS
All CF participants (n=252, ≥18 yrs without CFRD) underwent a 2h-OGTT with glucose and insulin sample measurements every 30 min. They were then classified as having either normal, impaired, or INDET glucose tolerance, or de novo CFRD. Other clinical characteristics were collected such as the BMI and pulmonary function.
RESULTS
All groups were of similar age (P=0.629) and BMI (P=0.813). We found that the INDETs displayed decreased lung function comparable to de novo CFRD. OGTT-derived glucose or insulin secretion/sensitivity parameters cannot fully explain this observation.
CONCLUSIONS
Prospective studies are required to establish if the INDET-CF group can identify clinically relevant outcomes.
背景
CFRD 之前和伴随有显著增加的发病率和死亡率。我们旨在描述一个在成年囊性纤维化 (CF) 患者中新建立的葡萄糖耐量亚组，命名为 INDET（不确定；1 小时口服葡萄糖耐量试验 (OGTT)>11.0，但 2 小时-OGTT<7.8 mmol/L）。
方法
所有 CF 参与者（n=252，无 CFRD，年龄≥18 岁）进行了 2 小时 OGTT，每 30 分钟测量一次葡萄糖和胰岛素样本。然后根据葡萄糖耐量将他们分为正常、受损或 INDET，或新诊断 CFRD。还收集了其他临床特征，如 BMI 和肺功能。
结果
所有组的年龄（P=0.629）和 BMI（P=0.813）相似。我们发现，与新诊断 CFRD 相比，INDETs 的肺功能下降。OGTT 衍生的葡萄糖或胰岛素分泌/敏感性参数不能完全解释这一观察结果。
结论
需要前瞻性研究来确定 INDET-CF 组是否可以识别临床相关的结果。
Zotero 插件